Forward Pharma A/SOver The Counter Market:FWPAY
- LAST PRICE2.8000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 2.8000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Forward Pharma A/S | 19.9M | -10.3x | --- |
Microbot Medical Inc | 20.6M | -1.2x | --- |
Neurosense Therapeutics Ltd | 18.9M | -1.5x | --- |
Edesa Biotech Inc | 18.7M | -1.2x | --- |
Akari Therapeutics PLC | 18.7M | -0.5x | --- |
PaxMedica Inc | 21.1M | -0.9x | --- |
Company Information
Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.
Contact Information
- Headquarters
- Oestergade 24A, 1, Copenhagen KCOPENHAGEN, Denmark 1100
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer
- Claus Svendsen
- Vice President - Finance, Controller, FP USA
- Thomas Carbone
- Chairman of the Board
- Florian Schonharting
- Director
- Torsten Goesch
- Director
- Jakob Larsen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $19.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 506.5K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.57 |
EPS | $-0.27 |
Book Value | $10.09 |
P/E Ratio | -10.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
